Skin test may personalize asthma care for kids
NCT ID NCT04699604
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tests whether a skin test that measures histamine response can help doctors decide if adding an antihistamine (Levocetirizine) to standard asthma treatment improves control in children aged 6-17 with allergic asthma. About 300 African American/Black and Caucasian/White children will be randomly assigned to receive either the antihistamine or a placebo for 6 weeks, then switch. The goal is to see if the skin test predicts who benefits most from antihistamine therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Levocetirizine (Xyzal)
- What this could lead to
- If successful, this could provide a simple skin test to identify which children with allergic asthma would benefit from adding an antihistamine to their current treatment.
- What could go wrong
- This is a Phase 3 trial, but it is still testing a biomarker approach. The antihistamine may not improve asthma control for all children, and results may vary by race or phenotype.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
55 people
The number who actually took part.
- Started
-
Apr 2021
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
6 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. A diagnosis of asthma based on physician diagnosis 2. A diagnosis of uncontrolled asthma based on Asthma Control Test (ACT) score within the last 3 months or at screening 3. Evidence of allergic sensitization based on allergy skin test or allergy blood test results 4. Individuals who are currently being treated with asthma guideline-based therapy 5. Males and females 6 through 17 years of age at time of enrollment 6. Willing to provide written permission/assent to participate 7. Children who self-identify as African American/black (identify both 1st degree (parents) and 2nd degree relatives (grandparents) as African American) or Caucasian/white (self-report of 1st and 2nd degree relatives as Caucasian) Exclusion Criteria: 1. For females, positive pregnancy test (by urinary hCG) or lactation at the time of the study 2. Any other chronic disease states such as history of premature lung disease, bronchiectasis, cystic fibrosis, or any chronic lung disease other than asthma. 3. Chronic abnormal conditions of the liver or kidney, immunologic/hematologic, or neoplastic disease as determined by the PI (the following questions will be asked at initial screening to identify children with potential abnormal kidney function: Have you ever been diagnosed with chronic kidney disease?; Have you ever had to be on dialysis or take medications for chronic kidney disease?) 4. Inability or unwillingness to have blood drawn as described in the protocol schedule of events and consent, or inability or unwillingness to cooperate with study procedures. 5. Clinically significant abnormal safety laboratory values as determined by study physician 6. Previous history of adverse drug reaction to Levocetirizine (LTZ) 7. Unwillingness or inability to washout of medications that affect histamine response 8. Active eczema at the site where histamine laser doppler probe will be place(forearm) on the day of histamine laser doppler iontophoresis 9. Age 18 years or older at the time of enrollment. 10. Those whom are pregnant, prisoners, and/or wards of the state. 11. Currently on or has been on Tricyclic Antidepresants in past 30 days
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allergic asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Mercy Hospital
Kansas City, Missouri, 64108, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your genes predict wood smoke harm?
- Allergy shots may unlock better asthma control by targeting hidden immune signals
- New asthma drug JYB1904 shows promise in early trial
- Cleveland clinic launches asthma research to develop better tests and treatments
- Cat allergy treatment gets a needle upgrade: fewer shots, same hope
- Biosimilar switch for asthma and hives under Real-World study